Compare Stocks: BLFS, INMD, and AXGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$51.47 -0.5%	$44.76	$15.24 ▼ $52.91	$2.78B	1.11	905,778 shs	771,143 shs
BLFS BioLife Solutions	$36.38 -2.2%	$31.43	$17.86 ▼ $38.10	$1.82B	1.93	641,048 shs	1.04 million shs
INMD InMode	$14.85 +0.1%	$14.98	$12.72 ▼ $16.74	$853.02M	1.89	402,378 shs	456,659 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	+0.29%	+11.39%	+25.71%	+31.03%	+220.51%
BLFS BioLife Solutions	+0.54%	+0.62%	+16.32%	+49.28%	+46.28%
INMD InMode	-0.60%	-0.54%	-4.07%	+6.53%	-2.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$51.47 -0.5%	$44.76	$15.24 ▼ $52.91	$2.78B	1.11	905,778 shs	771,143 shs
BLFS BioLife Solutions	$36.38 -2.2%	$31.43	$17.86 ▼ $38.10	$1.82B	1.93	641,048 shs	1.04 million shs
INMD InMode	$14.85 +0.1%	$14.98	$12.72 ▼ $16.74	$853.02M	1.89	402,378 shs	456,659 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	+0.29%	+11.39%	+25.71%	+31.03%	+220.51%
BLFS BioLife Solutions	+0.54%	+0.62%	+16.32%	+49.28%	+46.28%
INMD InMode	-0.60%	-0.54%	-4.07%	+6.53%	-2.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	2.75	Moderate Buy	$51.56	0.17% Upside
BLFS BioLife Solutions	2.18	Hold	$31.38	-13.76% Downside
INMD InMode	2.00	Hold	$16.00	7.74% Upside

Current Analyst Ratings Breakdown

Latest BLFS, INMD, and AXGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	AXGN AxoGen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/26/2026	AXGN AxoGen	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$60.00
8/10/2026	BLFS BioLife Solutions	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/6/2026	INMD InMode	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
7/30/2026	AXGN AxoGen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $53.00
7/30/2026	AXGN AxoGen	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
7/30/2026	AXGN AxoGen	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$55.00
7/30/2026	AXGN AxoGen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00
7/30/2026	AXGN AxoGen	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$50.00 ➝ $55.00
7/29/2026	AXGN AxoGen	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
7/28/2026	BLFS BioLife Solutions	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$225.21M	12.29	N/A	N/A	$4.77 per share	10.79
BLFS BioLife Solutions	$96.21M	18.48	$0.22 per share	162.46	$8.60 per share	4.23
INMD InMode	$370.49M	2.30	$1.49 per share	9.95	$10.94 per share	1.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$15.70M	-$0.68	N/A	1,029.40	N/A	-13.36%	-8.90%	-6.47%	11/4/2026 (Estimated)
BLFS BioLife Solutions	-$4.59M	$1.16	31.36	227.38	N/A	53.29%	2.70%	2.49%	11/5/2026 (Estimated)
INMD InMode	$93.83M	$1.23	12.07	N/A	N/A	20.69%	11.99%	10.60%	10/28/2026 (Estimated)

Latest BLFS, INMD, and AXGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BLFS BioLife Solutions	$0.0313	$0.91	+$0.8788	$0.91	$27.80 million	$28.47 million
8/5/2026	Q2 2026	INMD InMode	$0.3460	$0.35	+$0.0040	$0.29	$94.89 million	$95.59 million
7/29/2026	Q2 2026	AXGN AxoGen	$0.1214	$0.12	-$0.0014	-$0.03	$67.10 million	$69.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
BLFS BioLife Solutions	N/A	N/A	N/A	N/A	N/A
INMD InMode	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.07	6.60	5.04
BLFS BioLife Solutions	N/A	9.69	7.14
INMD InMode	N/A	8.18	7.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
BLFS BioLife Solutions	93.24%
INMD InMode	68.04%

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.44%
BLFS BioLife Solutions	2.20%
INMD InMode	6.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	53.76 million	52.45 million	Optionable
BLFS BioLife Solutions	440	48.86 million	47.78 million	Optionable
INMD InMode	480	57.48 million	53.50 million	Optionable

BLFS, INMD, and AXGN Headlines

Recent News About These Companies

InMode (NASDAQ:INMD) Stock Price Passes Above 200 Day Moving Average - Time to Sell?

August 25 at 2:00 AM | americanbankingnews.com

InMode (NASDAQ:INMD) Stock Price Crosses Above 200-Day Moving Average - Here's Why

August 25 at 1:59 AM | marketbeat.com

InMode Ltd. (NASDAQ:INMD) Given Average Recommendation of "Hold" by Brokerages

August 16, 2026 | marketbeat.com

Steadtrust LLC Boosts Position in InMode Ltd. $INMD

August 10, 2026 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

August 9, 2026 | theglobeandmail.com

InMode: Q2 Earnings Snapshot

August 5, 2026 | chron.com

InMode (NASDAQ:INMD) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

August 5, 2026 | marketbeat.com

InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025

August 5, 2026 | prnewswire.com

Prospect Capital Advisors LLC Boosts Holdings in InMode Ltd. $INMD

August 2, 2026 | marketbeat.com

InMode (NASDAQ:INMD) Governance Update Draws Fresh Focus

July 30, 2026 | kalkinemedia.comK

Renaissance Technologies LLC Acquires 149,800 Shares of InMode Ltd. $INMD

July 29, 2026 | marketbeat.com

Altshuler Shaham Ltd Has $1.64 Million Stake in InMode Ltd. $INMD

July 29, 2026 | marketbeat.com

Steel Partners Urges InMode Shareholders to Vote AGAINST the Re-Election of Dr. Hadar Ron and AGAINST Extraordinary Special Committee Compensation at the July 30 Annual General Meeting

July 28, 2026 | businesswire.com

InMode to Report Second Quarter 2026 Financial Results on August 5, 2026, Expects Q2 Revenue Between $95.2M-$95.4M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

July 13, 2026 | prnewswire.com

InMode Confirms Receipt of Unsolicited Proposal

July 10, 2026 | prnewswire.com

Steel Partners offers to acquire InMode at $16.75 per share cash deal; stock rises premarket

July 9, 2026 | msn.com

InMode shares jump after Steel Partners tables higher takeover proposal (INMD)

July 9, 2026 | msn.com

Steel Partners Offers to Acquire InMode for $16.75 Per Share in Cash

July 9, 2026 | businesswire.com

Securities Fraud Investigation Into InMode Ltd. (INMD) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud ...

July 2, 2026 | tmcnet.com

Securities Fraud Investigation Into InMode Ltd. (INMD) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

July 2, 2026 | businesswire.com

Steel Partners comes out against `value-destructive' CEO-led buyout offer for InMode

July 2, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS, INMD, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

$51.47 -0.26 (-0.50%)

As of 04:00 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

BioLife Solutions NASDAQ:BLFS

$36.38 -0.82 (-2.20%)

As of 04:00 PM Eastern

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

InMode NASDAQ:INMD

$14.85 +0.01 (+0.07%)

As of 04:00 PM Eastern

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BLFS, INMD, and AXGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BLFS, INMD, and AXGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BLFS, INMD, and AXGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS, INMD, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

BioLife Solutions NASDAQ:BLFS

InMode NASDAQ:INMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BLFS, INMD, and AXGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BLFS, INMD, and AXGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BLFS, INMD, and AXGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS, INMD, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

BioLife Solutions NASDAQ:BLFS

InMode NASDAQ:INMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools